FundraiseJul 6, 2026, 08:38 UTC

Adbiotech bets $6.5M on pet-health firm Onheal for 12% stake

What's the deal? Adbiotech, a Kosdaq-listed immune-antibody biotech, is investing 9,969,790,000 KRW (about $6.5 million) to acquire a 12.28% stake in pet-healthcare company Onheal. The deal makes it Onheal's second-largest shareholder, behind chief executive officer Kim Do-hyung.

Why now? Adbiotech's board approved the purchase of 181,269 shares on July 3, days after appointing Kim as chief executive officer in June 2026. Since then it has moved to broaden its portfolio across bio R&D, medical and healthcare, pets, and digital platforms.

What's the endgame? Onheal operates on a "One Health" model, spanning non-clinical CRO work, drug and device design and distribution, animal-drug licensing, the VETUS veterinary prescription platform, and pet-healthcare R&D. Adbiotech plans to use the stake to expand cooperation in pet healthcare and pursue new business.

By the numbers: The purchase equals 29.25% of Adbiotech's equity, a meaningful bet from a company built around egg-yolk antibody (IgY), nanobody (VHH), and mini-antibody (scFv) platforms for disease prevention and treatment in livestock, aquaculture, and pets.

What could go wrong? Onheal is an unlisted, small-to-mid-sized firm, so the deal is unlikely to reshape the market. Its significance rests mainly on Adbiotech's portfolio shift and its pet-healthcare growth story.

The signal: The investment tracks a wider "pet-conomy" push in South Korea, where pharma and biotech firms are expanding into animal medicine through subsidiaries, joint ventures, and stake purchases. "This share acquisition is part of a business diversification strategy for sustainable growth," a company representative said.